company? Let’s change
that.
Don't see your company?
Create a company profileVectra® is the leader in threat detection and response – from cloud and data center workloads to user and IoT devices. Its Cognito® platform accelerates threat detection and investigation using AI to enrich network metadata it collects and stores with the right context to detect, hunt and investigate known and unknown threats in real time. Vectra offers four applications on the Cognito platform to address high-priority use cases. Cognito Stream™ sends security-enriched metadata to data lakes and SIEMs. Cognito Recall™ is a cloud-based application to store and investigate threats in enriched metadata. Cognito Detect™ uses AI to reveal and prioritize hidden and unknown attackers at speed. And Cognito Detect for Office 365 and Azure AD™ finds and stops attacks in enterprise SaaS applications and the Microsoft 365 ecosystem. For more information, visit vectra.ai.
Brain monitoring is not easily accessible, interpretable or actionable. We're going to fix this, and we'd like you to help. With improved access to brain data and the right tools to act on it, clinicians could intervene in real-time, match life-altering therapies to the patients they benefit most, and treat previously untreatable neurological and psychiatric diseases. Beacon is building an interdisciplinary and uniquely talented team to implement this future.
Outcomes4Me is an AI-driven patient empowerment platform that helps cancer patients navigate their care and gain access to personalized treatment options. The company is on a mission to democratize healthcare by providing real-time, evidence-based clinical information to cancer patients, ensuring they can take a more active role in their own care. At the same time, Outcomes4Me is working to promote health equity by generating deeper insights that improve care, accelerate research, and lead to better outcomes. Based in Boston, Massachusetts, Outcomes4Me is a woman-led company of seasoned healthcare, oncology, pharmaceutical, consumer, and technology veterans.
Ankura Consulting Group, LLC is an independent global expert services and advisory firm that delivers services and end-to-end solutions to help clients at critical inflection points related to change, risk, disputes, finance, performance, distress, and transformation. The Ankura team consists of more than 1,500 professionals in more than 30 offices globally who are leaders in their respective fields and areas of expertise. Collaborative lateral thinking, hard-earned experience, expertise, and multidisciplinary capabilities drive results and Ankura is unrivaled in its ability to assist clients to Protect, Create, and Recover Value.
CyberArk is the global leader in Identity Security. Centered on privileged access management, CyberArk provides the most comprehensive security offering for any identity – human or machine – across business applications, distributed workforces, hybrid cloud workloads and throughout the DevOps lifecycle. The world’s leading organizations trust CyberArk to help secure their most critical assets. For over a decade CyberArk has led the market in securing enterprises against cyber attacks that take cover behind insider privileges and attack critical enterprise assets. Today, only CyberArk is delivering a new category of targeted security solutions that help leaders stop reacting to cyber threats and get ahead of them, preventing attack escalation before irreparable business harm is done. At a time when auditors and regulators are recognizing that privileged accounts are the fast track for cyber attacks and demanding stronger protection, CyberArk’s security solutions master high-stakes compliance and audit requirements while arming businesses to protect what matters most. With offices and authorized partners worldwide, CyberArk is a vital security partner to more than 6,770 global businesses, including: More than 50% of the Fortune 500 More than 35% of the Global 2000 CyberArk has offices in the U.S, Israel, U.K., Singapore, Australia, France, Germany, Italy, Japan, Netherlands and Turkey.
Bioreactors and operating systems for the industrial production of cultivated meat
We are Bicycle Therapeutics, a clinical-stage biopharmaceutical company. We didn’t wait for the next advance against cancer. We created it. Based on groundbreaking work conceived in the laboratory of Sir Greg Winter with the help of Professor Christian Heinis, we are pioneering the development of bicyclic peptides, or Bicycles® – a novel class of versatile, chemically synthesized medicines. Bicycles are fully synthetic short peptides constrained to form two loops which stabilize their structural geometry. This constraint is designed to confer high affinity and selectivity, and the relatively large surface area presented by the molecule allows targets to be drugged that have historically been intractable to non-biological approaches. Bicycles represent a unique therapeutic class, combining the pharmacological properties normally associated with a biologic with the manufacturing and pharmacokinetic advantages of a small molecule, yet with no signs of immunogenicity observed to date. Bicycles can be used as Bicycle conjugates to deliver toxin payloads and to precisely target local immune activation within tumors and as Bicycle T-cell modulators, which activate cytotoxic T-cells while circumventing the limitations of antibody and biologic therapies and better enabling combination therapy. Our lead product candidate, BT1718, is a Bicycle toxin conjugate currently being investigated in a Phase I/IIa open label dose escalation and expansion clinical trial sponsored by Cancer Research UK. BT1718 targets Membrane Type 1 Matrix Metalloproteinase (MT1-MMP), also known as MMP-14, which is highly expressed in many solid tumors. Our strategic collaborations are based on the ability of Bicycles to address a wide variety of targets. Through collaborations with AstraZeneca, Oxurion, Innovate UK and the Dementia Discovery Fund, we work with companies that have deep therapeutic expertise outside of oncology to enable us to more efficiently develop novel medicines for patients.
We are a biotechnology company pioneering new treatment options for neurodegenerative diseases by utilizing our proprietary RNA interference platform. We were founded by Anastasia Khvorova, Ph.D., Craig Mello, Ph.D., and Neil Aronin, M.D., of the RNA Therapeutics Institute at the University of Massachusetts Medical School, with a Series A funding exclusively by F-Prime Capital. We are headquartered in Boston, Mass.
A real estate company with a purpose; we are building the first modern real estate platform, pairing the industry’s top talent with technology to make the search and sell experience intelligent and seamless.
Atavistik Bio is a new, privately-held biopharmaceutical company focused on the discovery and development of novel therapies for metabolic diseases and cancer. Our high-throughput platform for the unbiased identification of metabolite-protein interactions will enable the discovery of first-in-class drugs inspired and empowered by nature’s own mechanisms of allosteric control. Our unique approach marries this validated platform with structure-aided drug design capabilities and cutting-edge insights into the regulation of metabolic systems to apply to genetically validated targets.
More than 1,000 top employers trust Bright Horizons® (NYSE: BFAM) for proven solutions that support employees, advance careers, and maximize performance. From on-site child care that amplifies your culture, back-up care to handle disruptions, and education programs that build critical skills, our services help families achieve more.
Virtusa Corporation is a global provider of Digital Business Transformation, Digital Engineering, and Information Technology (IT) outsourcing services that accelerate our clients’ journey to their Digital Future. Virtusa serves Global 2000 companies in Banking, Financial Services, Insurance, Healthcare, Telecommunications, Media, Entertainment, Travel, Manufacturing, and Technology industries. Using a combination of digital strategy, digital engineering, business implementation, and IT platform modernization services, Virtusa helps clients execute successful end-to-end digital business transformation initiatives. Virtusa engages its clients to re-imagine their business models and develop strategies to defend and grow their business by introducing innovative products and services, developing distinctive digital consumer experiences, creating operational efficiency using digital labor, developing operational and IT platforms for the future, and rationalizing and modernizing their existing IT applications infrastructure. As a result, its clients are simultaneously able to drive business growth through digital-first customer experiences, while also consolidating and modernizing their IT application infrastructure to support digital business transformation. Holding a proven record of success across industries, Virtusa readily understands its clients' business challenges and uses its domain expertise to deliver innovative applications of technology to address its clients’ critical business challenges. Examples include building the world's largest property & casualty claims modernization program; one of the largest corporate customer portals for a premier global bank; an order to cash implementation for a multinational telecommunications provider; and digital transformation initiatives for media and banking companies. Founded in 1996 and headquartered in Massachusetts, Virtusa has operations in North America, Europe, and Asia.
Pixability is a technology and data company that empowers the world's largest brands and their agencies to maximize the value of video advertising on YouTube, YouTube CTV, Amazon Fire, Roku and Hulu. The company’s industry-leading optimization and insights solutions are independently verified by the YouTube Measurement Program, DoubleVerify, Oracle Data Cloud’s Moat Measurement, Integral Ad Science and other third parties. Pixability’s suite of solutions are used by the top media agencies and brands including Dentsu-Aegis, Havas, Interpublic Group, Omnicom, Publicis, and GroupM, as well as Swatch, Bose, KIND, Hilton, Jack in the Box, and Puma.
Sungage Financial provides industry-leading solar financing that's more than just a loan. We're here to help our partners shine. Solar installers choose Sungage because they get the support and expertise of a team that goes the extra mile to make their lives easier and help them succeed.
Asimov builds tools to program living cells. By integrating mammalian synthetic biology, computer-aided design, and machine learning, our multi-disciplinary team is advancing the design and manufacture of biologics and gene therapies.
We aspire to build transformative precision medicines for patients with cancer and other serious conditions
Aetion is a health care SaaS and services company leveraging the science of causal inference to rapidly and transparently transform real-world data (RWD) into real-world evidence (RWE) on the safety, effectiveness, and value of medications and clinical interventions.
Board’s Intelligent Planning Platform delivers solutions that help over 2,000 organizations worldwide plan smarter — enabling actionable insights and better outcomes. Board helps leading enterprises discover crucial insights which drive business decisions and unify strategy, finance and operations through more integrated and intelligent planning to achieve full control of performance. Partnering with Board, global enterprises such as H&M, BASF, Burberry, Toyota, Coca-Cola, KPMG, and HSBC have deployed end-to-end planning applications at a fraction of the time and cost associated with traditional solutions. Board International was founded in 1994 and now has 25 offices around the world and a global reseller network. Board has been implemented in over 100 countries. Board International has long been recognized by leading analysts and subject matter experts including Gartner, Nucleus, and Dresner. Headquartered in Switzerland and US, Board International has branches in Argentina, Australia, Benelux, Nordics, Germany, France, India, Italy, Japan, Mexico, Singapore, Spain, UAE and UK and a worldwide network of distributors and certified partners. Board International is an equal opportunity employer and is committed to a diverse and inclusive workforce.
Founded in 2018 in Dublin by experienced security practitioners, Tines makes teams more effective and efficient.
Addgene is a self-sustaining, thriving nonprofit life sciences organization that was created to help scientists share DNA-based research materials called plasmids. Our mission is to accelerate research and discovery by improving access to useful research materials and information. Since its founding in 2004, Addgene has grown and innovated in order to assist the research community by archiving and sharing useful DNA-based research materials and resources (such as plasmids, viral vectors, and recombinant antibodies) with scientists worldwide. Broad availability of these unique research materials promotes the advancement of research in a wide variety of disciplines, including cancer, heart disease, and neurodegenerative disorders, while increasing collaboration within the scientific community. As an “Addgenie”, you will work collaboratively with internal teams to help fulfill this mission, including scientists, software engineers and product developers, renowned customer support teams, scientific content creators, and business development professionals. Together, Addgenies create and enhance opportunities for research scientists to deposit their materials, find products and resources easily on our website, and receive unparalleled support in receiving and expertly using our materials in their own experiments.